Samsung Biologics Co Ltd

Samsung Biologics Co Ltd

207940 · KO · Healthcare / Biotechnology

1,350,000.00KRW-16000.00 (-1.17%)

Price History

Full chart

Market Stats

Previous Close1,366,000.00
Open1,375,000.00
Day Range1,338,000.00 – 1,380,000.00
52-Week Range1,150,000.00 – 1,973,601.63
Volume17.71K
Market Cap65.69T
P/E (TTM)36.48
Forward P/E34.97
EPS39,724.83
Dividend Yield0.00%
Beta0.15
50-Day Avg1,000,000.00
200-Day Avg1,000,000.00

About

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. John Chongbo Rim
  • Employees5.33K
  • Headquarters300, Songdo bio-daero, Incheon, South Korea, Korea
  • Websitehttps://samsungbiologics.com

Leadership

  • Mr. John Chongbo RimCEO, President & Chairman of Board · b. 1961
  • Dr. Kun Lo Ph.D.Executive VP, Head of EPCV Center & Director · b. 1963
  • Mr. Seung ho RyuEVP, CFO, Head of Business Support Center & Director · b. 1968
  • Mr. Kevin SharpEVP, Head of Sales & Operations Department
  • Mr. Kyuho LeeExecutive VP, Head of People Center, & Chief Human Resource Officer
  • Mr. James J. ChoiExecutive VP, Head of CDO Development Center & Head of Sales Center · b. 1967
  • Mr. Heekyun LimVP & Head of Business Consulting Team · b. 1975
  • Sojeong LeeVP & Head of Regulatory Affairs
  • Ms. Heejeong KimVP & Head of Drug Substance Department
  • Mr. Sangmyung LeeVP & Head of CDO Development

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue105.15B91.28B294.62B464.63B535.81B701.59B1.16T1.57T3.00T3.69T3.50T4.56T
Growth (%)--13.19%+222.77%+57.70%+15.32%+30.94%+66.02%+34.62%+91.41%+23.10%-5.34%+30.31%
Cost of Revenue125.85B116.81B268.09B332.83B390.65B509.58B748.70B841.56B1.53T1.89T1.79T2.04T
Gross Profit-20.70B-25.54B26.53B131.80B145.16B192.01B416.08B726.45B1.47T1.80T1.71T2.52T
Gross Margin-19.69%-27.98%9.01%28.37%27.09%27.37%35.72%46.33%48.93%48.79%48.93%55.23%
Operating Expense98.84B178.11B56.96B65.82B89.48B100.27B123.29B189.14B484.82B689.08B389.82B447.42B
Operating Income-119.54B-203.64B-30.42B65.98B55.68B91.74B292.79B537.31B983.63B1.11T1.32T2.07T
Operating Margin-113.69%-223.10%-10.33%14.20%10.39%13.08%25.14%34.27%32.77%30.14%37.78%45.41%
EBITDA----40.38B410.26B313.94B425.77B737.78B1.38T1.69T2.02T2.78T
EBITDA Margin----8.69%76.57%44.75%36.55%47.05%46.03%45.78%57.71%61.04%
Net Income-95.91B1.92T-176.82B-96.97B224.11B202.90B240.97B393.59B798.06B857.69B1.08T1.78T
Net Income Margin-91.21%2103.66%-60.02%-20.87%41.83%28.92%20.69%25.10%26.59%23.21%30.98%39.16%
R&D186.74M-----5.11B954.22M45.88B81.59B36.71B37.18B
R&D as % of Total Revenue0.18%-----0.44%0.06%1.53%2.21%1.05%0.82%
Interest Expense000015.84B25.61B16.09B14.71B64.06B81.60B34.12B29.17B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%2.96%3.65%1.38%0.94%2.13%2.21%0.98%0.64%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.36T5.96T7.53T7.18T5.98T5.91T6.42T7.97T16.58T16.05T17.34T11.06T
Total Liabilities724.97B3.19T3.45T3.21T1.82T1.56T1.83T2.98T7.60T6.22T6.43T3.61T
Total Equity598.14B2.77T4.08T3.98T4.16T4.35T4.60T4.99T8.98T9.83T10.90T7.45T
Cash96.29B34.51B230.34B358.09B17.62B125.10B28.85B47.41B890.82B367.94B391.22B148.85B
Net Debt---187.82B855.07B512.72B733.51B1.23T1.21T1.26T948.54B769.87B

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-108.30B-265.51B-62.66B149.82B-33.02B10.15B202.09B454.60B953.05B1.67T1.66T2.25T
Investing Cash Flow-581.83B-429.48B-1.37T265.19B-631.39B339.64B-418.69B-933.49B-3.11T---
Financing Cash Flow682.02B633.22B1.63T-287.18B323.94B-239.81B122.56B496.62B3.00T---
Capital Expenditure365.93B240.33B168.17B494.12B278.65B192.84B139.66B406.25B956.84B1.11T1.38T1.48T
Free Cash Flow----354.99B-316.88B-171.04B53.52B33.44B-56.18B560.90B281.73B772.73B
FCF to OCF----236.95%959.73%-1684.55%26.49%7.36%-5.89%33.66%16.98%34.38%

Earnings

Report DateMay 15, 2017Jul 24, 2017Oct 25, 2017Jan 31, 2018Apr 24, 2018Jul 23, 2018Oct 23, 2018Jan 31, 2019Apr 24, 2019Jul 23, 2019Oct 23, 2019Jan 22, 2020Apr 20, 2020Jul 21, 2020Nov 16, 2020Mar 30, 2021Apr 28, 2021Aug 17, 2021Nov 15, 2021Mar 2, 2022May 16, 2022Aug 16, 2022Nov 14, 2022Mar 9, 2023Apr 24, 2023Aug 14, 2023Nov 14, 2023Feb 28, 2024May 16, 2024Aug 14, 2024Nov 14, 2024Feb 25, 2025May 15, 2025Aug 14, 2025Nov 14, 2025Feb 25, 2026May 15, 2026Aug 14, 2026Oct 27, 2026Jan 20, 2027
EPS Estimate--175.50-154.0037.3399.00206.00212.504849.61-130.38-118.52311.95866.18839.40947.204098.276554.671174.432008.463064.762256.372798.862445.923622.994337.942128.633629.504833.924733.114060.435187.035186.375062.185919.317073.8910335.5211382.979544.899873.549718.0010195.26
EPS Actual-494.61-334.00-479.00-153.00-865.00-145.00-455.004795.00-581.00-203.00667.003184.00547.52776.80930.212349.35911.213008.963119.661199.003279.562215.592798.326863.561992.003992.985190.726279.303874.596869.715713.486945.058113.587008.098071.008723.0010148.009314.00--
Surprise--90.31%-211.04%-509.86%-973.74%-170.39%-314.12%-1.13%-345.62%-71.28%113.82%267.59%-34.77%-17.99%-77.30%-64.16%-22.41%49.81%1.79%-46.86%17.17%-9.42%-22.76%58.22%-6.42%10.01%7.38%32.67%-4.58%32.44%10.16%37.19%37.07%-0.93%-21.91%-23.37%6.32%-5.67%--
TimingAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap65.69T
Enterprise Value66.48T
Trailing P/E36.48
Forward P/E34.97
PEG Ratio1.59
Price / Sales12.83
Price / Book8.07
EPS39,724.83
Book Value179,619.85
Revenue (TTM)5.12T
Gross Profit (TTM)2.78T
EBITDA2.83T
Profit Margin38.75%
Operating Margin45.48%
Return on Equity18.53%
Return on Assets9.57%
Shares Outstanding46.55M
Shares Float11.80M
Beta0.15
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Oct 30, 20250.6504:1